ARISTOS 10 VETERINARY

Land: Israel

Språk: engelsk

Kilde: Ministry of Health

Aktiv ingrediens:

MARBOFLOXACIN

Tilgjengelig fra:

ROMAT LTD

Legemiddelform:

SOLUTION FOR INJECTION

Sammensetning:

MARBOFLOXACIN 100 MG / 1 ML

Administreringsrute:

S.C, I.M, I.V

Resept typen:

Required

Produsert av:

FATRO S.P.A., ITALY

Indikasjoner:

In cattle: Treatment of respiratory infections with susceptible strains of Pasteurella multocida, Mannheimia (Pasteurella) haemolytica and Mycoplasma bovis.Treatment of acute Escherichia coli mastitis susceptible to marbofloxacin during the lactation period. In sows: Treatment of Metritis-Mastitis-Agalactic Syndrome with bacterial strains sensitive to marbofloxacin.

Autorisasjon dato:

2020-07-19

Informasjon til brukeren

Page 1 of
CONSUMER LEAFLET FOR A VETERINARY PRODUCT
This medicine is marketed according to a veterinarian’s prescription
only.
For animal use only
1.
NAME OF THE VETERINARY MEDICINE, FORM AND STRENGTH
ARISTOS 10 VETERINARY, SOLUTION FOR INJECTION
2.
ACTIVE INGREDIENT and quantity in a single dose:
Marbofloxacin 100 mg/ml
EXCIPIENTS – each ml contains:
Metacresol (2 mg), Thioglycerol ( 1 mg), Disodium edetate (0.1 mg)
For a full list of excipients, see section 13: "additional
information".
3.
WHAT IS THE MEDICINE INTENDED FOR
IN CATTLE:
-Treatment of respiratory infections with susceptible strains of
Pasteurella multocida,
Mannheimia (Pasteurella) haemolytica and Mycoplasma bovis.
-Treatment of acute Escherichia coli mastitis susceptible to
marbofloxacin during the
lactation period. IN SOWS:
Treatment of Metritis-Mastitis-Agalactic Syndrome with bacterial
strains sensitive to
marbofloxacin.
Therapeutic group: fluoroquinolone.
4.
CONTRA-INDICATIONS
Do not administer in the event of bacteria resistant to other
fluoroquinolones (cross-
resistance).
Do not administer to an animal with known hypersensitivity to
marbofloxacin or to another
quinolone.
5.
SIDE EFFECTS
Administration by the intramuscular route may cause transient local
reactions such as pain
and swelling at the injection site and inflammatory lesions which
persist at least 12 days
after injection.
However, in cattle, subcutaneous route was shown to be better
tolerated locally than
intramuscular route. Therefore, the subcutaneous route is recommended
in adult cattle. For
the injections, the neck should be preferred in cattle and pigs.
No other undesirable effects have been observed in cattle and pigs.
Side effects can be reported to the Ministry of Health by clicking on
the link "Adverse
Drug Reactions Repot" that appears on the home page of the Ministry of
Health web site
(www.health.gov.il), which leads to an online form for reporting side
effects. Alternatively
you can use the following link: HTTPS://SIDEEFFECTS.HEALTH.GOV.IL/
6.
TARGET ANIMALS: Catt